Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow supportT C Shea, M Flaherty, A Elias, et al.Head & Neck|August 15, 2000
Genetic polymorphisms in head and neck cancer riskJ E McWilliams, A J Evans, T M Beer, et al.Cancer Research|November 15, 1989
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistanceY Y Wang, B A Teicher, T C Shea, et al.Cancer Research|November 1, 1990
Glutathione transferase activity and isoenzyme composition in primary human breast cancersT C Shea, G Claflin, K E Comstock, et al.Cancer Research|July 1, 1988
Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemiaA M Deffie, T Alam, C Seneviratne, et al.Cancer Research|January 15, 1987
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II)B A Teicher, S A Holden, M J Kelley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancerJ P Eder, K Antman, W Peters, et al.Cancer Treatment Reports|February 1, 1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experienceK Antman, J P Eder, A Elias, et al.Neurosurgery|July 1, 1995
Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasmsP C Williams, W D Henner, S Roman-Goldstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.Pageof 6